Insurance Dropped Your GLP-1? The Complete Appeal Playbook for CVS Caremark, Cigna, Aetna, UHC (2026)

Two specific 2026 events drive most of the “insurance dropped my GLP-1” queries: (1) the CVS Caremark July 2025 formulary swap that removed Zepbound from most commercial formularies in favor of Wegovy as the preferred step, and (2) the BMI clawback pattern — insurance covers your Wegovy or Zepbound for 6-12 months, you lose weight, your BMI falls below the coverage threshold, and reauthorization is denied at the next refill window. This playbook covers all four phases of recovery: (1) internal appeal with a Letter of Medical Necessity, (2) external review through the independent review organization, (3) cash-pay bridge while the appeal is in flight, (4) switch-brand strategies. Verbatim payer-policy quotes from Cigna and Aetna throughout.

Why insurance drops GLP-1 coverage in 2026

Five common scenarios surface in the 2026 patient-experience data:

1. CVS Caremark July 2025 Wegovy-preferred swap — CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) removed Zepbound from MOST commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1 for weight loss. This formulary edit overrides bulletin 6947-C at point-of-sale on the affected formulary codes (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). A patient previously approved for Zepbound under bulletin 6947-C may receive a denial in 2026 even when they meet the same criteria. The fastest resolution is to switch to Wegovy under bulletin 4774-C.
2. BMI clawback at reauthorization — many plans only cover continued therapy when the patient maintains BMI above the original PA threshold (BMI ≥30, or ≥27 with comorbidity). Patients who lose enough weight to drop below the threshold are denied reauthorization at month 12 (Wegovy) or month 8 + 12 (Aetna 4774-C 7-month + 12-month sequence). Verbatim from Cigna IP0206 §III.1.B: “Approve for 1 year if … iii. Patient has lost ≥ 5% of baseline body weight; AND iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.” The 5% maintenance threshold is permissive — most patients who lost meaningfully will stay above it. The BMI threshold is the harder gate.
3. Step therapy not satisfied — Cigna CNF 360 verbatim p.3 (for Mounjaro, Trulicity, Victoza, Bydureon BCise): “If criteria for previous use of an oral medication for diabetes (not including Rybelsus or single-entity metformin) in the past 130 days are not met at the point of service … coverage will be determined by Prior Authorization criteria.” Patients who have only ever been on metformin for type 2 diabetes are denied Mounjaro at the pharmacy because metformin alone doesn't satisfy the step.
4. Documentation gap on reauthorization — the prescriber didn't submit the required attestation (e.g., the verbatim ≥5% weight-loss attestation; or the updated 6-month behavioral/dietary modification trial documentation per Aetna 4774-C). The PA system rejects and the pharmacy can't fill.
5. Plan changed obesity-medication policy — some employer plans removed all anti-obesity medications from the formulary entirely after the GLP-1 cost surge. Patients lose coverage at the next plan year transition even with a perfect clinical case.

Phase 1 — Internal appeal with Letter of Medical Necessity

Both Cigna and Aetna allow 180 days from the denial date to submit a written internal appeal on commercial plans (different deadlines apply to Medicare Part D / Medicare Advantage and to ERISA self-funded plans). Steps:

1. Request the written denial letter. The letter must specify which policy clause your submission failed to satisfy (per ACA 45 CFR §147.136 requirements). Example: “denied because patient does not have a documented 6-month comprehensive weight-management program per bulletin 4774-C.” That clause is your appeal target.
2. Get the actual policy document. Don't rely on the denial letter's paraphrase. Pull the verbatim PDF from the payer website (Cigna PDFs at static.cigna.com; Aetna PDFs at aetna.com/products/...) and read the specific clause your submission failed.
3. Have your prescriber draft a Letter of Medical Necessity (LOMN) that addresses the specific clause cited. Generic LOMN templates fail because they don't engage with the verbatim policy language. Use our GLP-1 PA letter generator which embeds the specific Cigna IP0206 / Aetna 4774-C / 6947-C clauses into the letter template.
4. File the internal appeal within the deadline (180 days commercial; 60 days Medicare). Include: the LOMN, the baseline + current BMI documentation, comorbidity documentation, prior medication trial history (especially if step therapy is the issue), the documented behavioral / dietary modification trial (3 months Cigna; 6 months Aetna), and (if reauth) the documented baseline weight-loss calculation. Submit via the payer's electronic appeal portal where available; track the case number.
5. Plan for the timeline. Standard internal appeals must be decided within 30 days for ongoing treatment denials and 60 days for completed-treatment denials per ACA. Expedited appeals (where delay would jeopardize health) must be decided within 72 hours.

Phase 2 — External review through the IRO

If the internal appeal is denied, you have the right to an external review by an independent review organization (IRO) under ACA. Key facts:

• You have 4 months from the final internal denial to request external review (some states have shorter windows; Cigna offers 2 levels of internal appeal in some plans).
• External review is binding on the plan. If the IRO overturns the denial, the plan must cover the drug.
• Expedited external review is available when delay would jeopardize health — must be decided within 72 hours.
• Standard external review typically takes 45 days from the request date.
• External review is free to the patient — payer pays for the IRO.
• Self-funded ERISA plans are not always subject to ACA external review — some are governed separately under ERISA federal regulations. Check your Summary Plan Description.
• External review is the right place to challenge a denial based on a medical-necessity disagreement (e.g., the plan says you don't have an “eligible comorbidity” but your prescriber documented one). External review is NOT for plan-design disputes (e.g., if the plan explicitly excludes all anti-obesity medications from the formulary, external review will uphold that exclusion).

Phase 3 — Cash-pay bridge while the appeal is in flight

Internal + external appeals can take 30-90 days during which you may not be able to get the medication. Cash-pay options verified live 2026-05-09:

For the full channel-by-channel guide with verbatim 2026 prices, see Wegovy GoodRx + Cash-Pay Coupon & Channel Guide. Brand and compounded GLP-1s are generally HSA/FSA eligible with a prescription per IRS Publication 502 — meaning you can pay from your HSA/FSA debit card during the appeal window.

Phase 4 — Switch-brand strategies

Sometimes the fastest resolution to a denial is not appealing — it's switching to a brand your formulary covers. The right switch depends on which brand your plan rejected:

• Denied Zepbound on a CVS Caremark formulary — switch to Wegovy. Bulletin 6981-A P04-2025 documents the formulary codes where Wegovy is the preferred step (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). Wegovy under Aetna 4774-C / Cigna IP0206 will typically approve cleanly on the same patient. Note: tirzepatide produces greater mean weight loss than semaglutide per SURMOUNT-5 (NEJM 2025), so the switch may reduce your weight-loss trajectory — but covered Wegovy is better than denied Zepbound.
• Denied Wegovy at the BMI 27-29.9 threshold — review whether your prescriber documented one of Cigna's 11 listed comorbidities (per IP0206 §III.1.A verbatim): hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, polycystic ovarian syndrome, or coronary artery disease. PCOS, knee OA, and MASLD/NAFLD are commonly overlooked. Resubmit with one of these properly documented.
• Denied Mounjaro for type 2 diabetes — check whether the metformin step is satisfied. Verbatim from Cigna CNF 360 + Aetna 5468-C: a non-metformin, non-Rybelsus oral antidiabetic must be in the 130-day lookback. Single-entity metformin and Rybelsus do NOT satisfy the step. Add a sulfonylurea, DPP-4, SGLT2, or TZD trial to the chart and resubmit.
• Denied Mounjaro for off-label weight loss (no T2D diagnosis) — switch to Zepbound (the weight-management-indicated tirzepatide brand from the same manufacturer). Same molecule, same dose, same tolerability — different brand name + different policy gate.
• Denied Ozempic for off-label weight loss — switch to Wegovy (same molecule, weight-management indication).
• Denied any weight-management GLP-1 with no clear path — consider Foundayo (orforglipron oral GLP-1, FDA-approved April 2026, $149/month at LillyDirect / Amazon Pharmacy). New drug with the same FDA-approved weight-management indication; some plans haven't yet updated their PA criteria for it.
• Denied because plan excludes all anti-obesity medications — your only paths are (a) HR escalation requesting a benefit-design change at the next plan year, (b) a different plan at next open enrollment, or (c) cash-pay alternatives indefinitely. Appeals will uphold the explicit exclusion.

Medicare-specific path: the GLP-1 Bridge

Aetna and Cigna Medicare Advantage Part D members get a new coverage path effective July 1, 2026 through the CMS-mandated Medicare GLP-1 Bridge:

• Drugs included: Wegovy (all formulations), Zepbound KwikPen only (NOT vials or single-dose pens), Foundayo (all formulations).
• Drugs excluded: Saxenda is NOT in the bridge. Mounjaro/Ozempic/Rybelsus continue under their existing T2D Part D coverage.
• Eligibility: BMI ≥ 27 plus heart disease or prediabetes.
• Cost: $50/month flat copay.
• Caveats: the $50 copay does NOT count toward the deductible OR toward the $2,100 out-of-pocket cap. The bridge runs through December 31, 2027; coverage after that reverts to whatever Part D rules exist at that time.

Pre-bridge (before 07/01/2026), MA-PD weight-loss-only coverage is statutorily prohibited (Social Security Act §1860D-2(e)(2)(A)). Wegovy MACE indication and Zepbound OSA indication remain Part D-coverable on most MA-PD plans because the indication is non-weight-loss.

Pre-appeal documentation checklist

Before the LOMN goes out, confirm your chart has:

• Baseline BMI with measured (not patient- reported) height and weight at the start of therapy
• Current BMI with measured weight at the most recent encounter
• Comorbidity diagnosis — ICD-10 code(s) for each comorbidity that satisfies the BMI 27-29.9 pathway (Cigna's 11-condition list per IP0206 verbatim, or Aetna's comorbidity criteria per 4774-C)
• Prior medication trial history — every oral antidiabetic in the 130-day lookback for diabetes GLP-1s; every prior weight-loss drug or program for weight-management GLP-1s
• 3- or 6-month behavioral / dietary modification documentation — Cigna IP0206 requires 3 months; Aetna 4774-C requires 6 months. The chart needs to show behavioral modification + reduced-calorie diet + (per Aetna) increased physical activity. A single line in the assessment is usually enough; zero documentation is the common failure point.
• Reauthorization weight-loss attestation (if reauth) — Wegovy/Zepbound/Foundayo/Saxenda all require ≥5% baseline body-weight loss for continuation. Saxenda is the exception with a 4% threshold per Aetna 1227-C. Pediatric Wegovy is ≥1% BMI reduction.
• Concomitant lifestyle attestation — every GLP-1 PA requires the prescriber to attest that the drug is being used “concomitantly with behavioral modification and a reduced-calorie diet.”

Practical takeaways

• The CVS Caremark July 2025 swap is real and ongoing. If you were previously approved for Zepbound and got denied in 2025-2026 with no clinical change, this is almost always why. Switching to Wegovy is the fastest fix.
• Generic LOMN templates fail. Your prescriber needs to engage with the verbatim policy clause cited in the denial letter. The PA letter generator we ship embeds the actual Cigna/Aetna criteria into the letter — see GLP-1 PA letter generator.
• External review is binding on the plan and free to the patient. Most patients never use it because the internal appeal succeeds. But if the internal appeal is denied, request external review — IROs frequently overturn payer decisions when the medical-necessity case is strong.
• Cash-pay bridge options are cheaper than ever. NovoCare $299/month Wegovy + LillyDirect $299-$449/month Zepbound + $149/month Foundayo make out-of-pocket survivable for most patients during a 60-90 day appeal window. See our cash-pay coupon & channel guide.
• Medicare GLP-1 Bridge starts 07/01/2026. If you're an Aetna or Cigna MA-PD member with BMI ≥27 + heart disease / prediabetes, mark the date.